Hypertension and diabetes mellitus co-exist in approximately 70–80% of patients with type 2 diabetes, and each condition dramatically amplifies the cardiovascular and renal risk conferred by the other. In a patient with both conditions, the risk of myocardial infarction, stroke, heart failure, and end-stage renal disease is multiplicative rather than simply additive.1,2 Optimal management of hypertension in diabetes therefore requires not merely lowering BP but selecting agents that confer independent cardiorenal protection, avoiding agents that worsen metabolic parameters, and integrating the antihypertensive regimen with the broader framework of diabetes pharmacotherapy, including the emerging antihypertensive properties of SGLT2 inhibitors and GLP-1 receptor agonists.
In type 2 diabetes, insulin resistance is the primary pathophysiological mechanism linking diabetes to hypertension through several converging pathways.3 Compensatory hyperinsulinemia in the setting of insulin resistance stimulates the sympathetic nervous system (SNS) through central mechanisms. Insulin normally promotes vasodilation via NO release from the endothelium; in insulin resistance, this vasodilatory arm is preserved while the metabolic arm of glucose disposal is impaired, creating a state of endothelial dysfunction with paradoxical sympathetic overactivation. SNS activation increases cardiac output and promotes renal sodium retention.
Insulin resistance is associated with upregulated sodium-hydrogen exchanger activity (NHE3) in the renal proximal tubule, promoting sodium reabsorption, and hyperinsulinemia independently activates renal tubular sodium transporters. Sodium retention expands intravascular volume and raises BP. This mechanism underpins why SGLT2 inhibitors, which directly counter proximal tubular sodium avidity, are particularly effective in this setting. Adipose tissue (particularly visceral) expresses all RAAS components, and adipokines including dysregulated leptin and adiponectin upregulate angiotensinogen and RAAS activity. Angiotensin II worsens insulin resistance by inhibiting insulin receptor substrate-1 (IRS-1) signaling in skeletal muscle, creating a bidirectional feedback between RAAS activation and insulin resistance.
Advanced glycation end products (AGEs) quench NO and cross-link extracellular matrix proteins stiffening arteries, protein kinase C activation in hyperglycemia increases endothelin-1 and reduces NO production, and oxidative stress from glucotoxicity further reduces NO bioavailability. Obstructive sleep apnea (OSA) is highly prevalent in type 2 diabetes and obesity and independently causes hypertension through SNS activation and aldosterone excess, representing a frequently underappreciated contributor.
In type 1 diabetes, hypertension develops primarily in the context of diabetic nephropathy. Patients with type 1 diabetes are typically normotensive before the onset of microalbuminuria. The development of microalbuminuria signals glomerular hypertension and initiates the hypertension-nephropathy cycle.4 Glomerular hyperfiltration in early diabetic nephropathy results from reduced tubuloglomerular feedback, afferent arteriolar dilation, and increased GFR, with intraglomerular hypertension developing before systemic BP rises. Microalbuminuria develops as the glomerular filtration barrier becomes permeable to albumin. Systemic hypertension develops as nephron loss progresses and renal sodium excretory capacity decreases. RAAS activation from ischemic nephrons amplifies hypertension. The key pharmacological implication is that in type 1 diabetes, RAAS inhibition initiated at the microalbuminuria stage can prevent progression to overt nephropathy and attenuate the development of systemic hypertension.
Type 2 diabetes is frequently embedded within the metabolic syndrome: central obesity, dyslipidemia, hypertension, and insulin resistance. This cluster dramatically increases cardiovascular risk. Antihypertensive agent selection must account for metabolic consequences. Thiazide diuretics and beta-blockers, particularly non-selective or non-vasodilatory agents, worsen insulin resistance and glucose tolerance and require metabolic monitoring. RAAS inhibitors and CCBs are metabolically neutral or favorable and are preferred. SGLT2 inhibitors reduce visceral adiposity, lower BP, and improve all components of the metabolic syndrome.
The United Kingdom Prospective Diabetes Study (UKPDS, 1998) established that tight BP control below 150/85 mmHg, achieved with captopril or atenolol, reduced diabetes-related deaths by 32%, stroke by 44%, and microvascular complications by 37% compared with less tight control below 180/105 mmHg.5 UKPDS established that blood pressure control was more important than glycemic control for preventing macrovascular complications in type 2 diabetes, and that both ACEi (captopril) and beta-blocker (atenolol) were effective for BP lowering, though neither conferred a specific advantage over the other beyond BP reduction in this trial.
The Hypertension Optimal Treatment (HOT) trial (1998) enrolled 18,790 hypertensive patients including a large diabetic subgroup.6 In patients with diabetes, a target diastolic BP of 80 mmHg or below (versus 90 mmHg or below) produced a significant reduction in cardiovascular events, one of the first trials to support a lower diastolic target specifically in diabetes.
The ACCORD BP trial (2010) randomized 4,733 patients with type 2 diabetes and high cardiovascular risk to an intensive systolic BP target below 120 mmHg versus a standard target below 140 mmHg.7 Intensive control did not significantly reduce the primary composite cardiovascular endpoint but did produce a significant 41% relative risk reduction in stroke, accompanied by a significant increase in adverse events including acute kidney injury (AKI), hypotension, hypokalemia, and bradycardia in the intensive group. The practical implication is that a target of below 130/80 mmHg is supported and appropriate for most patients with type 2 diabetes, capturing most of the stroke benefit with a more manageable adverse event profile, while targeting below 120 mmHg is not routinely recommended. SPRINT excluded patients with diabetes and its findings are not directly applicable to this population, though the ACCORD-SPRINT pooled analysis suggests that the stroke benefit of intensive BP lowering may be real and that BP reduction per se reduces stroke in diabetes.
The ACC/AHA 2017 guideline recommends a target BP below 130/80 mmHg for patients with diabetes and hypertension, regardless of CKD or proteinuria status.1 The ADA Standards of Medical Care recommend below 130/80 mmHg for most patients with diabetes and hypertension, with below 140/90 mmHg acceptable if lower targets are not achieved without excessive medication burden or adverse effects.2 The 2018 ESC/ESH guideline recommends below 130/80 mmHg for most patients with diabetes, with a systolic of 120–130 mmHg preferred in many cases and a diastolic of 70–80 mmHg, while avoiding diastolic below 70 mmHg in patients with established coronary artery disease.9 The 2023 ESH guideline recommends a systolic target of 120–130 mmHg in patients below 65 years with diabetes and 130–140 mmHg in those 65 or above or with significant comorbidities.10 In practical terms, most patients with type 2 diabetes and hypertension should target below 130/80 mmHg when achievable without unacceptable adverse effects, and lower targets below 120 mmHg systolic should not be routinely pursued given ACCORD BP findings.
ACEi or ARBs are the preferred first-line antihypertensive agents in most patients with diabetes, particularly when any degree of albuminuria is present.1,2 RAAS inhibitors reduce intraglomerular pressure through efferent arteriolar dilation, providing renoprotection independent of BP lowering; they exert an antiproteinuric effect that slows CKD progression in diabetic nephropathy; and they reduce the incidence of new-onset type 2 diabetes versus beta-blockers and thiazides by approximately 20–25%.
Cardiovascular outcome evidence includes the HOPE trial (ramipril reduced cardiovascular events by 22% in high-risk patients including those with diabetes) and UKPDS (captopril). In type 1 diabetic nephropathy, the Lewis et al. (1993) trial established that captopril reduced doubling of serum creatinine and end-stage renal disease (ESRD) by 50%. In type 2 diabetic nephropathy, the RENAAL (losartan) and IDNT (irbesartan) trials established renoprotection independent of BP reduction. ACEi are preferred in type 1 diabetic nephropathy where the direct evidence is strongest, while ARBs are preferred in type 2 diabetic nephropathy, where RENAAL and IDNT have FDA approval for this specific indication. Either is appropriate for hypertension without proteinuria when patient tolerability and cost guide selection. ACEi plus ARB combination (dual RAAS blockade) must not be used, as VA NEPHRON-D showed no benefit and excess harm.
CCBs are metabolically neutral and highly effective in diabetic hypertension.1,2 They have no adverse effects on glucose metabolism, insulin sensitivity, or lipids. Amlodipine is the preferred DHP CCB, supported by CAMELOT (antiatherosclerotic benefit) and ACCOMPLISH (superior cardiovascular outcomes versus hydrochlorothiazide (HCTZ) plus RAAS inhibitor). CCBs are equally effective in Black patients with diabetes as in other groups. Regarding proteinuria, DHP CCBs have less antiproteinuric effect than RAAS inhibitors in diabetic nephropathy, with IDNT demonstrating irbesartan superiority over amlodipine for renoprotection despite equivalent BP reduction. DHP CCBs should generally be combined with RAAS inhibitors rather than substituted for them in patients with significant albuminuria.
Thiazide and thiazide-like diuretics are effective antihypertensives in diabetes but require careful consideration of metabolic effects.1,2 At low doses (chlorthalidone 12.5 mg, HCTZ 12.5–25 mg, indapamide 1.25 mg), glucose effects are acceptable and generally manageable; indapamide has the most favorable metabolic profile of the thiazide-like agents and is essentially neutral for glucose at standard doses. At higher doses (HCTZ 50 mg, chlorthalidone 25–50 mg), significant hypokalemia impairs insulin secretion from pancreatic beta cells, worsening glycemic control, and the risk of glucose intolerance and new-onset diabetes increases. The guideline approach is to use the lowest effective thiazide dose, prefer chlorthalidone or indapamide over HCTZ, and ensure potassium is adequately replaced or use a RAAS inhibitor combination to blunt hypokalemia. Loop diuretics are required when eGFR falls below 30 mL/min/1.73m²; torsemide is preferred over furosemide for superior bioavailability.
Beta-blockers have important metabolic considerations in diabetes that influence agent selection.3 Non-selective agents cause adverse metabolic effects through beta-2 blockade in pancreatic beta cells (impairing insulin secretion), beta-2 blockade in skeletal muscle (impairing glycogenolysis and delaying recovery from hypoglycemia), masking of hypoglycemic symptoms (all symptoms are masked except diaphoresis), and raising triglycerides while lowering HDL. Beta-blockers remain indicated when a compelling indication exists: HFrEF (carvedilol, metoprolol succinate, bisoprolol), post-MI, atrial fibrillation rate control, or angina.
When a beta-blocker is required in a patient with diabetes, agent selection is important. Carvedilol, the combined alpha/beta-blocker, is preferred as it is neutral or favorable for metabolic effect and does not worsen insulin resistance, while having a favorable lipid profile. Nebivolol, which is highly cardioselective with NO-mediated vasodilation, has the least metabolic impact of all beta-blockers with the least glucose effect, least dyslipidemia, and least reported erectile dysfunction. Bisoprolol, the most cardioselective traditional agent, has an acceptable glucose effect at standard doses with once-daily dosing simplicity. Atenolol should be avoided: the LIFE trial demonstrated inferior cardiovascular outcomes compared to losartan, and atenolol carries a substantial metabolic burden while accumulating in CKD. Propranolol and other non-selective agents should be avoided without compelling indication.
Alpha-1 blockers such as doxazosin are metabolically neutral and may modestly improve insulin sensitivity. They are useful as add-on agents in resistant hypertension and particularly in men with concurrent benign prostatic hyperplasia (BPH). ALLHAT demonstrated increased heart failure with doxazosin versus chlorthalidone as monotherapy; doxazosin should be restricted to add-on use as in the general hypertensive population.
Spironolactone is an effective fourth-line agent for resistant hypertension (PATHWAY-2) and is metabolically neutral for glucose; aldosterone excess impairs glucose metabolism, so MRA therapy may modestly improve insulin sensitivity. Hyperkalemia risk is amplified in diabetic CKD on RAAS inhibition, and gynecomastia and sexual dysfunction are common reasons for discontinuation in men; eplerenone should be used if these are concerns. Finerenone, the non-steroidal MRA, has dual cardiovascular and renal outcome evidence in type 2 diabetic CKD from FIDELIO-diabetic kidney disease (DKD) and FIGARO-DKD, with a lower hyperkalemia risk than steroidal MRAs at antifibrotic doses and no sex hormone side effects. Finerenone is increasingly considered standard of care for type 2 diabetic CKD with significant albuminuria on background RAAS inhibition.
SGLT2 inhibitors have transformed the management of type 2 diabetes with cardiovascular disease or risk factors, providing antihypertensive benefit through multiple mechanisms.11,12 Their antihypertensive mechanisms include natriuresis and osmotic diuresis from reduced proximal tubular sodium and glucose reabsorption, producing a modest but consistent systolic BP reduction of 3–5 mmHg and diastolic reduction of 1–2 mmHg; weight loss of 2–3 kg of primarily visceral adiposity, reducing obesity-related hypertension mechanisms; reduction of intraglomerular pressure via tubuloglomerular feedback (complementary to RAAS inhibition, as detailed in HTN-07); and modest RAAS suppression through natriuresis-induced volume reduction.
Landmark cardiovascular outcome trials established the foundation of the class. EMPA-REG OUTCOME (2015) found that empagliflozin in type 2 diabetes with established cardiovascular disease produced a 38% reduction in cardiovascular death, a 35% reduction in heart failure hospitalizations, and a 39% reduction in the renal composite endpoint.11 CANVAS (2017) showed significant reductions in cardiovascular events, heart failure, and renal endpoints with canagliflozin. DECLARE-TIMI 58 (2019) found significant reduction in heart failure hospitalization and renal composite endpoint with dapagliflozin. Landmark renal outcome trials include CREDENCE (2019) with a 40% reduction in the primary renal composite with canagliflozin12 and DAPA-CKD (2020) demonstrating benefit independent of diabetes status, as covered in HTN-07.
SGLT2 inhibitors should be initiated in all patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD (eGFR 20 or above with albuminuria), in addition to metformin when tolerated and RAAS inhibition. They should not be used in type 1 diabetes outside of clinical trials due to the risk of euglycemic diabetic ketoacidosis.
GLP-1 receptor agonists including semaglutide, liraglutide, and dulaglutide have demonstrated cardiovascular outcome benefit and modest antihypertensive effects.13 Their antihypertensive mechanisms include significant weight reduction (subcutaneous semaglutide 2.4 mg produced a mean loss of 15–17 kg in the SURMOUNT-1 trial), natriuresis through direct renal GLP-1 receptor stimulation, and vasodilation through NO-mediated mechanisms, producing mean systolic BP reduction of approximately 2–5 mmHg and diastolic reduction of 1–2 mmHg. Cardiovascular outcome trials demonstrated their benefit: the LEADER trial (2016) found that liraglutide in type 2 diabetes with high cardiovascular risk produced a 13% reduction in 3-point major adverse cardiovascular events (MACE) and significant reduction in cardiovascular death;13 SUSTAIN-6 (2016) showed a 26% reduction in MACE with semaglutide and significant reduction in non-fatal stroke; REWIND (2019) found a 12% reduction in MACE with dulaglutide and significant reduction in the renal composite endpoint. GLP-1 receptor agonists are recommended as add-on therapy after metformin in type 2 diabetes with established cardiovascular disease or high cardiovascular risk, independently of glycemic control levels. Their modest BP-lowering effect is an added benefit rather than a primary antihypertensive indication.
When SGLT2 inhibitors are added to existing antihypertensive regimens, the additional natriuretic effect may cause volume depletion and symptomatic hypotension, particularly in elderly patients, those on loop diuretics or thiazides, or those at or below target BP. Reducing the diuretic dose when adding an SGLT2 inhibitor should be considered if volume depletion is a concern. BP and renal function should be monitored within 4 weeks of initiation. An initial eGFR dip of 5–10% is expected and acceptable, reflecting reduced intraglomerular pressure rather than nephrotoxicity, analogous to the creatinine rise with RAAS inhibitor initiation.
Patients with type 2 diabetes have a higher prevalence of resistant hypertension than the non-diabetic hypertensive population for several reasons: greater salt sensitivity; higher prevalence of aldosterone excess, including primary aldosteronism and hyperaldosteronism from insulin resistance; higher prevalence of OSA (present in approximately 80% of resistant hypertension patients); more complex medication regimens with adherence challenges; and CKD-related volume retention.
As outlined in HTN-06, true resistance requires verification of adherence, ambulatory blood pressure monitoring (ABPM) to exclude white coat hypertension, and review of BP-elevating medications. NSAIDs are particularly common in diabetic patients with neuropathic pain or musculoskeletal comorbidities; they raise BP by 3–5 mmHg on average and blunt both diuretic and RAAS inhibitor efficacy. OSA screening with polysomnography or home sleep study is essential. Aldosterone-to-renin ratio measurement is warranted, as primary aldosteronism is more prevalent in diabetes.
Spironolactone 25–50 mg daily remains the most effective fourth-line agent per PATHWAY-2 and should be the first choice when tolerated. Potassium should be monitored closely. Eplerenone should be substituted if gynecomastia occurs. In type 2 diabetic CKD with residual albuminuria on RAAS inhibitor plus SGLT2 inhibitor, finerenone 10–20 mg is the preferred MRA, given its dual cardiovascular and renal outcome evidence from FIDELIO-DKD and FIGARO-DKD. Doxazosin is an alternative fourth-line agent that is metabolically neutral and beneficial in concurrent BPH; ALLHAT evidence argues against monotherapy use. Bisoprolol or nebivolol should be considered if a beta-blocker indication exists and one is not already prescribed.
NSAIDs are frequently used in diabetes for peripheral neuropathy pain and musculoskeletal comorbidities. Acetaminophen is the preferred alternative for pain management. Duloxetine and pregabalin are appropriate for neuropathic pain. Topical diclofenac gel has substantially lower systemic absorption and BP effect than oral NSAIDs and is an option for localized musculoskeletal pain. Gabapentin can be considered for neuropathic pain with caution in CKD due to accumulation.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127–e248.
doi:10.1016/j.jacc.2017.11.006American Diabetes Association. Standards of Medical Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S1–S321.
doi:10.2337/dc24-SINTSowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37(4):1053–1059.
doi:10.1161/01.HYP.37.4.1053Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. Diabetes. 1983;32(Suppl 2):64–78.
doi:10.2337/diab.32.2.S64UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713.
doi:10.1136/bmj.317.7160.703Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension (HOT randomised trial). Lancet. 1998;351(9118):1755–1762.
doi:10.1016/S0140-6736(98)04311-6ACCORD Study Group; Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus (ACCORD BP). N Engl J Med. 2010;362(17):1575–1585.
doi:10.1056/NEJMoa1001286SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control (SPRINT). N Engl J Med. 2015;373(22):2103–2116.
doi:10.1056/NEJMoa1511939Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
doi:10.1093/eurheartj/ehy339Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071.
doi:10.1097/HJH.0000000000003480Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117–2128.
doi:10.1056/NEJMoa1504720Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). N Engl J Med. 2019;380(24):2295–2306.
doi:10.1056/NEJMoa1811744Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311–322.
doi:10.1056/NEJMoa1603827Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436–1446.
doi:10.1056/NEJMoa2024816Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). N Engl J Med. 2020;383(23):2219–2229.
doi:10.1056/NEJMoa2025845